O	0	4	PTTG	PTTG	NN	B-NP
O	5	19	overexpression	overexpression	NN	I-NP
O	20	28	promotes	promote	VBZ	B-VP
B-Multi-tissue_structure	29	34	lymph	lymph	NN	B-NP
I-Multi-tissue_structure	35	39	node	node	NN	I-NP
O	40	50	metastasis	metastasis	NN	I-NP
O	51	53	in	in	IN	B-PP
O	54	59	human	human	JJ	B-NP
B-Cancer	60	70	esophageal	esophageal	JJ	I-NP
I-Cancer	71	79	squamous	squamous	JJ	I-NP
I-Cancer	80	84	cell	cell	NN	I-NP
I-Cancer	85	94	carcinoma	carcinoma	NN	I-NP
O	94	95	.	.	.	O

O	97	102	Human	Human	JJ	B-NP
O	103	112	pituitary	pituitary	JJ	I-NP
O	113	118	tumor	tumor	NN	I-NP
O	119	131	transforming	transform	VBG	B-VP
O	132	136	gene	gene	NN	B-NP
O	137	138	(	(	(	O
O	138	142	PTTG	PTTG	NN	B-NP
O	142	143	)	)	)	O
O	144	158	overexpression	overexpression	NN	B-NP
O	159	169	correlates	correlate	VBZ	B-VP
O	170	174	with	with	IN	B-PP
O	175	185	metastasis	metastasis	NN	B-NP
O	186	188	in	in	IN	B-PP
O	189	197	multiple	multiple	JJ	B-NP
B-Cancer	198	204	tumors	tumor	NNS	I-NP
O	204	205	,	,	,	O
O	206	209	and	and	CC	O
O	210	213	yet	yet	RB	B-ADVP
O	214	217	its	its	PRP$	B-NP
O	218	227	molecular	molecular	JJ	I-NP
O	228	238	mechanisms	mechanism	NNS	I-NP
O	239	241	of	of	IN	B-PP
O	242	248	action	action	NN	B-NP
O	249	255	remain	remain	VBP	B-VP
O	256	263	elusive	elusive	JJ	B-ADJP
O	263	264	.	.	.	O

O	265	267	We	We	PRP	B-NP
O	268	276	detected	detect	VBD	B-VP
O	277	281	PTTG	PTTG	NN	B-NP
O	282	296	overexpression	overexpression	NN	I-NP
O	297	299	in	in	IN	B-PP
O	300	302	66	66	CD	B-NP
O	302	303	%	%	NN	I-NP
O	304	305	(	(	(	O
O	305	308	111	111	CD	B-NP
O	309	311	of	of	IN	B-PP
O	312	315	169	169	CD	B-NP
O	315	316	)	)	)	O
O	317	319	of	of	IN	B-PP
B-Tissue	320	327	primary	primary	JJ	B-NP
I-Tissue	328	338	esophageal	esophageal	JJ	I-NP
I-Tissue	339	347	squamous	squamous	JJ	I-NP
I-Tissue	348	352	cell	cell	NN	I-NP
I-Tissue	353	362	carcinoma	carcinoma	NN	I-NP
I-Tissue	363	364	(	(	(	O
I-Tissue	364	368	ESCC	ESCC	NN	B-NP
I-Tissue	368	369	)	)	)	O
I-Tissue	370	375	tumor	tumor	NN	B-NP
I-Tissue	376	383	tissues	tissue	NNS	I-NP
O	384	386	by	by	IN	B-PP
O	387	389	in	in	FW	B-NP
O	390	394	situ	situ	FW	I-NP
O	395	408	hybridization	hybridization	NN	I-NP
O	408	409	.	.	.	O

O	410	414	PTTG	PTTG	NN	B-NP
O	415	429	overexpression	overexpression	NN	I-NP
O	430	440	correlated	correlate	VBD	B-VP
O	441	445	with	with	IN	B-PP
B-Multi-tissue_structure	446	451	lymph	lymph	NN	B-NP
I-Multi-tissue_structure	452	456	node	node	NN	I-NP
O	457	467	metastasis	metastasis	NN	I-NP
O	468	469	(	(	(	O
O	469	470	P	P	NN	B-NP
O	471	472	<	<	SYM	B-ADJP
O	473	474	0	0	CD	B-NP
O	474	475	.	.	.	I-NP
O	475	477	05	05	CD	I-NP
O	477	478	)	)	)	O
O	478	479	.	.	.	O

O	480	487	Ectopic	Ectopic	JJ	B-NP
O	488	492	PTTG	PTTG	NN	I-NP
O	493	507	overexpression	overexpression	NN	I-NP
O	508	510	in	in	IN	B-PP
O	511	512	a	a	DT	B-NP
O	513	527	representative	representative	JJ	I-NP
B-Cell	528	532	ESCC	ESCC	NN	I-NP
I-Cell	533	537	cell	cell	NN	I-NP
I-Cell	538	542	line	line	NN	I-NP
O	542	543	,	,	,	O
B-Cell	544	550	EC9706	EC9706	NN	B-NP
O	550	551	,	,	,	O
O	552	561	increased	increase	VBN	B-VP
O	562	564	in	in	FW	B-NP
O	565	570	vitro	vitro	FW	I-NP
B-Cell	571	575	cell	cell	NN	I-NP
O	576	585	migration	migration	NN	I-NP
O	586	589	and	and	CC	I-NP
O	590	598	invasion	invasion	NN	I-NP
O	599	602	and	and	CC	O
O	603	611	promoted	promote	VBD	B-VP
O	612	614	in	in	FW	B-NP
O	615	619	vivo	vivo	FW	I-NP
B-Multi-tissue_structure	620	625	lymph	lymph	NN	I-NP
I-Multi-tissue_structure	626	630	node	node	NN	I-NP
O	631	641	metastasis	metastasis	NN	I-NP
O	641	642	.	.	.	O

O	643	654	Suppressing	Suppress	VBG	B-VP
O	655	659	PTTG	PTTG	NN	B-NP
O	660	670	expression	expression	NN	I-NP
O	671	673	by	by	IN	B-PP
O	674	679	siRNA	siRNA	NN	B-NP
O	680	689	decreased	decrease	VBD	B-VP
B-Cell	690	694	cell	cell	NN	B-NP
O	695	703	motility	motility	NN	I-NP
O	704	706	in	in	IN	B-PP
O	707	711	both	both	CC	O
B-Cell	712	716	PTTG	PTTG	NN	B-NP
I-Cell	716	717	-	-	HYPH	I-NP
I-Cell	717	719	HA	HA	NN	I-NP
I-Cell	719	720	/	/	SYM	I-NP
I-Cell	720	726	EC9706	EC9706	NN	I-NP
O	727	730	and	and	CC	I-NP
B-Cell	731	738	KYSE150	KYSE150	NN	I-NP
I-Cell	739	744	cells	cell	NNS	I-NP
O	744	745	.	.	.	O

O	746	748	By	By	IN	B-PP
O	749	754	using	use	VBG	B-VP
O	755	759	mass	mass	NN	B-NP
O	760	773	spectrometric	spectrometric	JJ	I-NP
O	774	782	analysis	analysis	NN	I-NP
O	782	783	,	,	,	O
O	784	786	we	we	PRP	B-NP
O	787	797	identified	identify	VBD	B-VP
O	798	802	that	that	IN	B-SBAR
O	803	807	PTTG	PTTG	NN	B-NP
O	808	810	up	up	RB	B-ADVP
O	810	811	-	-	HYPH	B-NP
O	811	820	regulated	regulate	VBN	I-NP
O	821	827	S100A4	S100A4	NN	I-NP
O	828	831	and	and	CC	I-NP
O	832	840	galectin	galectin	NN	I-NP
O	840	841	-	-	HYPH	B-NP
O	841	842	1	1	CD	I-NP
O	843	852	secretion	secretion	NN	I-NP
O	853	856	and	and	CC	O
O	857	861	down	down	RB	B-ADVP
O	861	862	-	-	HYPH	O
O	862	871	regulated	regulate	VBN	B-NP
B-Tissue	872	878	tissue	tissue	NN	I-NP
O	879	888	inhibitor	inhibitor	NN	I-NP
O	889	891	of	of	IN	B-PP
O	892	909	metalloproteinase	metalloproteinase	NN	B-NP
O	909	910	-	-	HYPH	B-NP
O	910	911	2	2	CD	I-NP
O	912	921	secretion	secretion	NN	I-NP
O	922	924	to	to	TO	B-PP
O	925	928	the	the	DT	B-NP
O	929	936	culture	culture	NN	I-NP
O	937	942	media	medium	NNS	I-NP
O	942	943	.	.	.	O

O	944	948	PTTG	PTTG	NN	B-NP
O	949	956	induced	induce	VBD	B-VP
O	957	963	S100A4	S100A4	NN	B-NP
O	964	967	and	and	CC	I-NP
O	968	976	galectin	galectin	NN	I-NP
O	976	977	-	-	HYPH	B-NP
O	977	978	1	1	CD	I-NP
O	979	983	mRNA	mRNA	NN	I-NP
O	984	987	and	and	CC	I-NP
O	988	995	protein	protein	NN	I-NP
O	996	1006	expression	expression	NN	I-NP
O	1007	1009	as	as	IN	B-SBAR
O	1010	1018	assessed	assess	VBN	B-VP
O	1019	1021	by	by	IN	B-PP
O	1022	1029	Western	Western	JJ	B-NP
O	1030	1034	blot	blot	NN	I-NP
O	1035	1038	and	and	CC	O
O	1039	1046	reverse	reverse	JJ	B-NP
O	1047	1060	transcription	transcription	NN	I-NP
O	1060	1061	-	-	HYPH	B-NP
O	1061	1064	PCR	PCR	NN	I-NP
O	1064	1065	.	.	.	O

O	1066	1077	Attenuating	Attenuate	VBG	B-VP
O	1078	1086	galectin	galectin	NN	B-NP
O	1086	1087	-	-	HYPH	O
O	1087	1088	1	1	CD	B-NP
O	1089	1099	expression	expression	NN	I-NP
O	1100	1102	by	by	IN	B-PP
O	1103	1108	siRNA	siRNA	NN	B-NP
O	1109	1120	constrained	constrain	VBD	B-VP
B-Cell	1121	1125	PTTG	PTTG	NN	B-NP
I-Cell	1125	1126	-	-	HYPH	B-NP
I-Cell	1126	1128	HA	HA	NN	I-NP
I-Cell	1128	1129	/	/	SYM	I-NP
I-Cell	1129	1135	EC9706	EC9706	NN	I-NP
I-Cell	1136	1140	cell	cell	NN	I-NP
O	1141	1149	motility	motility	NN	I-NP
O	1150	1151	(	(	(	O
O	1151	1152	P	P	NN	B-NP
O	1153	1154	<	<	SYM	B-ADJP
O	1155	1156	0	0	CD	B-NP
O	1156	1157	.	.	.	I-NP
O	1157	1159	05	05	CD	I-NP
O	1159	1160	)	)	)	O
O	1160	1161	.	.	.	O

O	1162	1166	PTTG	PTTG	NN	B-NP
O	1167	1176	activated	activate	VBD	B-VP
O	1177	1178	E	E	NN	B-NP
O	1178	1179	-	-	HYPH	B-NP
O	1179	1182	box	box	NN	I-NP
O	1183	1196	transcription	transcription	NN	I-NP
O	1197	1200	and	and	CC	O
O	1201	1208	induced	induce	VBD	B-VP
O	1209	1210	c	c	NN	B-NP
O	1210	1211	-	-	HYPH	B-NP
O	1211	1214	Myc	Myc	NN	I-NP
O	1215	1222	protein	protein	NN	I-NP
O	1223	1233	expression	expression	NN	I-NP
O	1234	1236	in	in	IN	B-PP
B-Cell	1237	1243	EC9706	EC9706	NN	B-NP
I-Cell	1244	1249	cells	cell	NNS	I-NP
O	1249	1250	,	,	,	O
O	1251	1256	which	which	WDT	B-NP
O	1257	1259	in	in	IN	B-PP
O	1260	1264	turn	turn	NN	B-NP
O	1265	1268	may	may	MD	B-VP
O	1269	1272	act	act	VB	I-VP
O	1273	1275	on	on	IN	B-PP
O	1276	1278	an	an	DT	B-NP
O	1279	1280	E	E	NN	I-NP
O	1280	1281	-	-	HYPH	I-NP
O	1281	1284	box	box	NN	I-NP
O	1285	1290	motif	motif	NN	I-NP
O	1291	1297	within	within	IN	B-PP
O	1298	1301	the	the	DT	B-NP
O	1302	1310	galectin	galectin	NN	I-NP
O	1310	1311	-	-	HYPH	B-NP
O	1311	1312	1	1	CD	I-NP
O	1313	1321	promoter	promoter	NN	I-NP
O	1321	1322	.	.	.	O

B-Cellular_component	1323	1332	Chromatin	Chromatin	NN	B-NP
O	1333	1352	immunoprecipitation	immunoprecipitation	NN	I-NP
O	1353	1359	assays	assay	NNS	I-NP
O	1360	1367	further	further	RBR	B-ADVP
O	1368	1377	confirmed	confirm	VBD	B-VP
O	1378	1386	specific	specific	JJ	B-NP
O	1387	1388	c	c	NN	I-NP
O	1388	1389	-	-	HYPH	B-NP
O	1389	1392	Myc	Myc	NN	I-NP
O	1393	1400	binding	binding	NN	I-NP
O	1401	1403	to	to	TO	B-PP
O	1404	1412	galectin	galectin	NN	B-NP
O	1412	1413	-	-	HYPH	B-NP
O	1413	1414	1	1	CD	I-NP
O	1415	1423	promoter	promoter	NN	I-NP
O	1423	1424	.	.	.	O

O	1425	1429	PTTG	PTTG	NN	B-NP
O	1429	1430	-	-	HYPH	B-PP
O	1430	1437	induced	induce	VBN	B-NP
O	1438	1446	galectin	galectin	NN	I-NP
O	1446	1447	-	-	HYPH	B-NP
O	1447	1448	1	1	CD	I-NP
O	1449	1464	transactivation	transactivation	NN	I-NP
O	1465	1468	and	and	CC	I-NP
O	1469	1479	expression	expression	NN	I-NP
O	1480	1484	were	be	VBD	B-VP
O	1485	1493	mediated	mediate	VBN	I-VP
O	1494	1496	by	by	IN	B-PP
O	1497	1498	c	c	NN	B-NP
O	1498	1499	-	-	HYPH	I-NP
O	1499	1502	Myc	Myc	NN	I-NP
O	1502	1503	,	,	,	O
O	1504	1507	and	and	CC	O
O	1508	1512	both	both	DT	B-NP
O	1513	1523	inductions	induction	NNS	I-NP
O	1524	1528	were	be	VBD	B-VP
O	1529	1539	suppressed	suppress	VBN	I-VP
O	1540	1542	by	by	IN	B-PP
O	1543	1544	c	c	NN	B-NP
O	1544	1545	-	-	HYPH	I-NP
O	1545	1548	Myc	Myc	NN	I-NP
O	1549	1553	RNAi	RNAi	NN	I-NP
O	1554	1567	cotranfection	cotranfection	NN	I-NP
O	1567	1568	.	.	.	O

O	1569	1574	These	These	DT	B-NP
O	1575	1583	findings	finding	NNS	I-NP
O	1584	1593	elucidate	elucidate	VBP	B-VP
O	1594	1597	the	the	DT	B-NP
O	1598	1607	molecular	molecular	JJ	I-NP
O	1608	1618	mechanisms	mechanism	NNS	I-NP
O	1619	1621	of	of	IN	B-PP
O	1622	1626	PTTG	PTTG	NN	B-NP
O	1627	1641	overexpression	overexpression	NN	I-NP
O	1642	1644	in	in	IN	B-PP
O	1645	1654	promoting	promote	VBG	B-VP
B-Cancer	1655	1660	tumor	tumor	NN	B-NP
O	1661	1671	metastasis	metastasis	NN	I-NP
O	1671	1672	,	,	,	O
O	1673	1680	whereby	whereby	WRB	B-ADVP
O	1681	1683	up	up	RB	B-ADVP
O	1683	1684	-	-	HYPH	I-ADVP
O	1684	1693	regulated	regulate	VBN	B-NP
O	1694	1698	PTTG	PTTG	NN	I-NP
O	1699	1708	modulates	modulate	VBZ	B-VP
O	1709	1719	expression	expression	NN	B-NP
O	1720	1723	and	and	CC	I-NP
O	1724	1733	secretion	secretion	NN	I-NP
O	1734	1736	of	of	IN	B-PP
O	1737	1747	metastasis	metastasis	NN	B-NP
O	1747	1748	-	-	HYPH	B-NP
O	1748	1755	related	relate	VBN	I-NP
O	1756	1763	factors	factor	NNS	I-NP
O	1764	1766	to	to	TO	B-VP
O	1767	1777	facilitate	facilitate	VB	I-VP
B-Cell	1778	1782	cell	cell	NN	B-NP
O	1783	1791	motility	motility	NN	I-NP
O	1791	1792	.	.	.	O

